Dako to Collaborate with Pfizer on Companion Diagnostics

Dako to Collaborate with Pfizer on Companion Diagnostics 
GLOSTRUP, DENMARK -- (Marketwire) -- 02/12/13 --  Dako, an Agilent
Technologies company, announced today it has entered into a
collaboration agreement with Pfizer in the field of companion
diagnostics. 
The agreement constitutes a legal framework for various collaboration
projects
between the two companies, covering research, development
and commercialization
as well as advisory services. 
"We are extremely excited to partner with Pfizer, a company with such
a global
presence and reputation for market leadership," said Lars
Holmkvist, CEO of Dako
and senior vice president, Agilent.  "This
collaboration is testimony to the
level of expertise and service Dako
is committed to delivering to our  partners
in companion
diagnostics." 
Companion diagnostics are seen as the cornerstones of precision
medicine. They
provide a way to improve patient care and reduce
health-care costs by matching
specific therapies to the individuals
most likely to benefit from them, since
all patients do not respond
in the same way. 
"This partnership with Dako will support Pfizer's companion
diagnostics efforts,
an important component of our growing Precision
Medicine capabilities," said
John Hubbard, senior vice president,
Development Operations at Pfizer. "Precision Medicine R&D is designed
to advance more targeted therapies for patients, improve efficacy,
safety and success rates, and expedite development." 
Financial terms of the agreement were not disclosed. 
Today's news follows an earlier announcement from Dako introducing a
master framework agreement between Dako and Eli Lilly and Company,
which focuses on
developing novel companion diagnostics for Eli
Lilly's oncology pipeline. 
About Dako - An Agilent Technologies Company 
Dako is relentless in its commitment to fighting cancer together with
customers
and strategic partners-because patients' lives depend on
companies continuing to bring scientific advancement to the diagnostic
and therapeutic fields. 
Dako, based in Denmark, is a global leader in tissue-based cancer
diagnostics.
Hospital and research laboratories worldwide use Dako's
reagents, instruments,
software and expertise to make accurate
diagnoses and determine the most effective treatment for cancer
patients. Dako, with 1,200 employees, operates in more than 100
countries. Dako became part of Agilent Technologies on June 21, 2012.
Information about Dako is available at www.dako.com. 
About Agilent Technologies 
Agilent Technologies Inc. (NYSE: A) is the world's premier
measurement company
and a technology leader in chemical analysis, life
sciences, diagnostics, electronics and communications. The company's
20,500 employees serve customers
in more than 100 countries. Agilent
had revenues of $6.9 billion in fiscal 2012. Information about
Agilent is available at www.agilent.com. 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Dako Denmark A/S via Thomson Reuters ONE 
[HUG#1677383] 
EDITORIAL CONTACT: 
Maia Fredtoft Sochting
Communications
+45 25 46 10 83
Dako Denmark A/S
maia.sochting@dako.com
 
 
Press spacebar to pause and continue. Press esc to stop.